Dipyridamole

Dipyridamole
Clinical data
Trade names	Persantine, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682830
Routes of; administration	By mouth, intravenous
ATC code	B01AC07 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	37–66%
Protein binding	~99%
Metabolism	Liver (glucuronidation)
Elimination half-life	α phase: 40 min,; β phase: 10 hours
Excretion	Biliary (95%), urine (negligible)
Identifiers
	IUPAC name 2,2',2'',2'''-(4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol;
CAS Number	58-32-2 ;
PubChem CID	3108;
IUPHAR/BPS	4807;
DrugBank	DB00975 ;
ChemSpider	2997 ;
UNII	64ALC7F90C;
KEGG	D00302 ;
ChEBI	CHEBI:4653 ;
ChEMBL	ChEMBL932 ;
CompTox Dashboard (EPA)	DTXSID6040668 ;
ECHA InfoCard	100.000.340
Chemical and physical data
Formula	C24H40N8O4
Molar mass	504.636 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO;
	InChI InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2 ; Key:IZEKFCXSFNUWAM-UHFFFAOYSA-N ;
	(verify)

Dipyridamole (trademarked as Persantine and others) is an antiplatelet drug of the nucleoside transport inhibitor and PDE3 inhibitor class that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.

^ Nielsen-Kudsk F, Pedersen AK (May 1979). "Pharmacokinetics of dipyridamole". Acta Pharmacologica et Toxicologica. 44 (5): 391–399. doi:10.1111/j.1600-0773.1979.tb02350.x. PMID 474151.
^ "Aggrenox (aspirin/extended-release dipyridamole) Capsules. Full Prescribing Information" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc. Retrieved 1 December 2016.